Suppr超能文献

甘薯(Caiapo)对2型糖尿病患者的作用机制。

Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patients.

作者信息

Ludvik Bernhard, Waldhäusl Werner, Prager Rudolf, Kautzky-Willer Alexandra, Pacini Giovanni

机构信息

3rd Department of Medicine, Division of Endocrinology and Metabolism, University of Vienna, Austria.

出版信息

Metabolism. 2003 Jul;52(7):875-80. doi: 10.1016/s0026-0495(03)00073-8.

Abstract

We have previously reported the beneficial effects of Caiapo, the extract of white-skinned sweet potato (ipomoea batatas), on fasting plasma glucose, as well as on total and low-density lipoprotein (LDL) cholesterol in type 2 diabetic patients. The present study aimed to describe the underlying mechanism responsible for the improvement in metabolic control following administration of Caiapo in those type 2 subjects. A total of 18 male patients (age=58+/-8 years, body mass index [BMI]=27.7+/-2.7 kg/m2, mean +/- SEM) treated only by diet were randomized into 3 groups (placebo, low-dose Caiapo, 2 g/d, and high-dose, 4 g/d). Parameters related to glucose tolerance, glucose disappearance, and insulin secretion were obtained by performing both frequently sampled intravenous glucose tolerance test (FSIGT) and oral glucose tolerance test (OGTT) before and after 6 weeks of treatment with Caiapo. Following treatment with high dose Caiapo, insulin sensitivity significantly ameliorated when assessed both with OGTT (from 308+/-13 mg/min/m2 to 334+/-10, P=.048) and FSIGT (from 1.21+/-0.32 10(4) min(-1)/(microU/mL) to 1.73+/-0.40, P=.021). Improvement of insulin sensitivity with the low dose was observed only with the FSIGT (from 2.02+/-0.70 10(4) min(-1)/(microU/mL) to 2.76+/-0.89, P<.05). Glucose effectiveness did not change. While no changes in glucose tolerance were observed in the placebo and low-dose groups, it increased from 0.85+/-0.13 %min(-1) to 1.46+/-0.13 (P<.02) in patients on high dose. No significant changes were seen in any of the parameters related to insulin dynamics: insulin secretion (from C-peptide), distribution, clearance, and hepatic extraction remained virtually the same after the treatment. In conclusion, short-term treatment with 4 g/d of the nutraceutical Caiapo consistently improved metabolic control in type 2 diabetic patients by decreasing insulin resistance without affecting body weight, glucose effectiveness, or insulin dynamics. No side effects related to the treatment were observed. Thus these results indicate that Caiapo could potentially play a role in the treatment of type 2 diabetes.

摘要

我们之前曾报道过,白皮肤红薯(甘薯)提取物Caiapo对2型糖尿病患者的空腹血糖以及总胆固醇和低密度脂蛋白(LDL)胆固醇具有有益作用。本研究旨在描述2型受试者服用Caiapo后代谢控制改善的潜在机制。总共18名仅接受饮食治疗的男性患者(年龄=58±8岁,体重指数[BMI]=27.7±2.7kg/m²,平均值±标准误)被随机分为3组(安慰剂组、低剂量Caiapo组,2g/天,和高剂量组,4g/天)。在接受Caiapo治疗6周前后,通过进行频繁采样静脉葡萄糖耐量试验(FSIGT)和口服葡萄糖耐量试验(OGTT),获得与葡萄糖耐量、葡萄糖消失和胰岛素分泌相关的参数。高剂量Caiapo治疗后,通过OGTT(从308±13mg/min/m²至334±10,P=0.048)和FSIGT(从1.21±0.32×10⁴min⁻¹/(μU/mL)至1.73±0.40,P=0.021)评估时,胰岛素敏感性显著改善。仅在FSIGT中观察到低剂量时胰岛素敏感性的改善(从2.02±0.70×10⁴min⁻¹/(μU/mL)至2.76±0.89,P<0.05)。葡萄糖效能未改变。虽然在安慰剂组和低剂量组中未观察到葡萄糖耐量的变化,但高剂量组患者的葡萄糖耐量从0.85±0.13%min⁻¹增加至1.46±0.13(P<0.02)。与胰岛素动力学相关的任何参数均未观察到显著变化:治疗后胰岛素分泌(来自C肽)、分布、清除和肝脏摄取基本保持不变。总之,每天4g营养保健品Caiapo的短期治疗通过降低胰岛素抵抗持续改善2型糖尿病患者的代谢控制,而不影响体重、葡萄糖效能或胰岛素动力学。未观察到与治疗相关的副作用。因此,这些结果表明Caiapo可能在2型糖尿病的治疗中发挥作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验